2 turnaround stocks I’d consider buying before 2018

Could these two turnaround stocks beat the market in 2018 and beyond?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Hikma Pharmaceuticals (LSE: HIK) has taken investors on a roller-coaster ride since listing on the stock market in 2005. Ten years of tremendous organic growth, supplemented by acquisitions, saw it promoted to the FTSE 100 in 2015. However, having reached a peak of over 2,600p last year, its shares have fallen back dramatically, hitting a new multi-year low of under 1,000p this month.

However, in its reduced circumstances (it’s been demoted back to the second-tier FTSE 250) and at its depressed share price, Hikma is one of two turnaround stocks I’d buy before 2018.

Recent difficulties

A trading statement last week was indicative of its recent difficulties. It reported a good performance from its Injectables business, steady improvement from its Branded business, but cut its forecasts for Generics for the third time this year.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

The company said that as a result of challenging market conditions impacting the US generics industry, it had experienced greater than expected price and volume erosion and that it expects these market conditions to persist in 2018. Also within Generics, it said it still hasn’t been able get the US Food and Drug Administration (FDA) to approve its generic version of GlaxoSmithKline‘s Advair.

Three reasons to buy

There are three reasons I rate Hikma a ‘buy’ before 2018. First, I reckon the subdued outlook for the Generics division is fully priced-in. Second, generic Advair could yet get the go-ahead, with the company having entered a dispute resolution process with the FDA, which it expects to complete in Q1 2018. Third, and most significantly, I calculate Hikma’s strong balance sheet gives it up to $1.5bn of firepower to pursue value-enhancing acquisitions, joint ventures or share buybacks. As such, I reckon the shares look cheap on current City earnings forecasts for 2018, which give a P/E of under 14.

Hidden value

In June, under its new chief executive, small-cap Molins (LSE: MLIN) announced the sale of its tobacco machinery division to focus on its higher-growth packaging machinery division. The shares were trading at 101.5p at the time and I calculated the fair value of the rejigged company as between 175p, based on my estimation of net asset value (NAV), and 197p, based on applying the same sales multiple at which the tobacco machinery division was sold to the forecast sales of the retained business.

The deal, and a subsequently announced sale of a Canadian property, didn’t complete before Molins’ half-year-end but there’s enough information in the half-year results to revise my fair value estimates. The sales-multiple-based value remains at 197p, but the NAV rises to 221p.

Balance sheet NAV at the half-year-end was £40.7m. So I remove book value of the Canadian property of £1.5m and tobacco machinery division assets of £38.6m and liabilities of £11.8m. Then I add net cash proceeds from the Canadian property sale of £5.9m, less £1m to adapt a new leased building, and net cash proceeds of £27.3m from the tobacco machinery division sale, of which £1.5m of warranty escrow goes into trade receivables and £2.7m into pension assets.

The result is a NAV of £44.6m, representing 221p a share. The shares are currently trading at around 140p. I reckon the value on offer here could attract wider attention when the company releases its annual results (with a clean balance sheet) in early 2018.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 reasons Tesla stock may be a long-term bargain

This writer is keen to buy Tesla stock at the right price. He doesn't think it's there yet -- but…

Read more »

Investing Articles

Nvidia stock is a lot cheaper than before – or is it?

Nvidia stock has been caught in the whirlwind of market volatility. This writer has been waiting to buy, so might…

Read more »

Top Stocks

3 FTSE stocks Fools are eyeing up for choppy markets

A selection of companies listed on the UK stock market on the watchlists of four Foolish investors.

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

A £10,000 investment in Rolls-Royce shares last week is now worth this…

Harvey Jones says Rolls-Royce shares couldn't escape the volatility of recent weeks, but wonders if the recent dip is a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Prediction: in 2 years these S&P 500 stocks will be much higher than they are today

These two S&P 500 stocks have been beaten down in recent weeks. But Edward Sheldon expects them to move much…

Read more »

Investing Articles

10% yields! Why a volatile stock market is great news for passive income investors

The recent stock market volatility has given passive income investors the chance to earn double-digit returns. But they still need…

Read more »

Close up of manual worker's equipment at construction site without people.
Investing Articles

Down 65% from its highs, this FTSE 250 stock is one to consider buying low

Shares in a strong FTSE 250 company going through a cyclical downturn have caught Stephen Wright’s attention as a potential…

Read more »

Investing Articles

£20,000 invested in a Stocks and Shares ISA 5 years ago is now worth…

Stocks and Shares ISA investors have reaped enormous returns since the pandemic, but how much money have they actually made?…

Read more »